Cell therapy developers Athersys and Cytomedix target the immense stroke treatment market. Mr. Napodano laid out the theses for these two stem cell developers, although he’s more bullish on CMXI for the time being. News this week that Trius had patented a tidezolid/daptomycin combination has an interesting read-through for Trius and Cubist. Mr. King called TSRX a buy when [...]
For those that missed it last week, Dr. Chaudhry offered an educational, retrospective look at both AVEO and DCTH’s advisory panel votes. In addition, we listed a few reasons that investors might find AVEO interesting over the next few months. It’s a wildcard, but bottom-fishers might take a peek. While we were optimistic about the [...]
This week was dominated by a number of binary events (which we outlined on Monday), two of which played out against us; Dr. Chaudhry expected that the FDA’s oncologic advisory panel would vote in favor of AVEO and DCTH. Here’s where AVEO went awry, and next week she’ll recap the DCTH panel outcome. (P.S. the AVEO [...]
Synergy’s equity financing, which wrapped up last Tuesday, put the company in a strong position for a partnership (or M&A) negotiation regarding plecanatide. The stock continued to demonstrate weakness following the pricing of the offering as investors moved on to stories with more catalysts upcoming. But we think they’ve missed a few events, and this [...]
ICPT has a big problem, and could be headed back to its post-IPO prices, 50% lower than where they trade today. The company piqued our interest with the realization that pressure on the stock was a result of a lock-up expiration on the majority of ICPT’s outstanding shares. But the digging led us down a [...]
Keryx (KERX) has come back under the magnifying glass at PropThink. We hosted Dr. Scott Chambers, a patent attorney and former USPTO staff, on a conference call this week with our subscribers. The call cleared up a lot of unanswered questions about Zerenex’s IP protection, and our readers who were involved at the beginning of [...]
PropThink kicked off the week by revisiting Endo Health (ENDP) and brought the scoop on Rajiv De Silva’s materializing plans for the company. De Silva, a former Valeant (VRX) star, was brought in as Endo’s CEO in February, and he’s been on the road with investors this week outlining his plan for moving forward. Based [...]
Cadence (CADX) was a compelling buy last year as the sales ramp for its IV acetaminophen formulation began to improve. A position since Mr. King first wrote on the name in December has returned more than 60%, but we believe it’s time to take profits. Early in the week, Mr. King took a retrospective look [...]
Although Illumina was slapped with a $96M fine by a federal jury this week, the monetary penalty isn’t all that detrimental to the $6B company; Illumina is out-pacing its competition in the genetic sequencing market. Amedisys operates a declining business, we believe, which should start to reflect more on the stock. The home healthcare provider [...]
We kicked off the week with a quick technical blurb about Sarepta Therapeutics, although we didn’t get into the details of our bullish long-term outlook. On Wednesday, Mr. King laid out a little more in regards to the upcoming early filing and explained why SRPT investors should keep some powder dry. PropThink Premium provides actionable [...]
Jason Napodano laid out the DRRX investment thesis. Will Pfizer re-file the Remoxy NDA? And what about Posidur? They’re both real value drivers for DRRX, and under the right circumstances, investors could be looking at a double catalyst early next year. The story brought in a quick 6% trade on Tuesday. PropThink’s subscribers jumped into [...]
On Friday, PropThink launched its database of Special Protocol Assessments, or SPAs. These trials are, in essence, a FDA-blessed measure to mitigate clinical efficacy risk (learn more by visiting PropThink’s SPA landing page) The database is a new and unique facet to PropThink, something that we’ve yet to see widely available elsewhere, and provides a [...]
PropThink’s first story of the week turned into a whopping 24% gainer by Friday’s close. We iterated our enthusiasm for Pharmacyclics (PCYC) on Monday, following which, the stock took off like a NASA rocket when Ibrutinib received Breakthrough Therapy Designation. It’s the first oncology company to receive the FDA’s new acceleration, a major milestone for [...]
IMUC proved a successful trade in the short-term, climbing 34% since our report was published on the first of the month. In early trials, lead candidate ICT-107 demonstrated impressive efficacy in patients with glioblastoma multiforme, and at its relatively low valuation, is a cheap opportunity in the cancer space. Numerous sources have pointed to the [...]
The event of the week? Phase III data for Zerenex, Keryx Biopharmaceutical’s phosphate binder, were released on Monday, with compelling results. PropThink has been covering KERX since last fall, and the stock was up 230% (from $2.92, our initiation price) at its peak this week. Depomed (DEPO), for which our report went public on Tuesday, [...]
The highlight of our week was Allergan’s ~$1B buyout of MAP Pharmaceuticals, a company that we recommended in early January. The acquisition came at a 60% premium to MAPP’s closing price, but all-in-all for AGN, the deal was a bargain if Levadex lives up to its potential. Mr. Napodano sat down with management from Zalicus [...]
The FDA will decide on Lymphoseek’s approval in April, a major catalyst for Navidea (NAVB). Interest will again build in the some-what controversial name, and we expect the stock will climb significantly. On Wednesday, PropThink suggested using options to play Celsion’s ThermoDox data release. They’ve only gotten cheaper since. Was the sell-off a precursor to [...]
We spent the week in San Francisco for the JP Morgan and Biotech Showcase conferences, which proved invaluable for idea generation, networking, and the solidifying of some in-process stories. We’ll have more to write in the coming weeks, and suggest the conference for all of those interested in life science investing. Affymax picked up another crucial supply [...]
A catalyst-rich 2013 and a solid financial position for BioMarin should push the stock higher. Since we published this story on Monday, shares of the drug developer are up 9%. Dendreon’s rally in the new year is largely a product of the JP Morgan Healthcare conference next week and a number of bullish Seeking Alpha articles, [...]
Following the Phase III failure of Oncothyreon’s lead candidate Stimuvax, we see some value remaining in the oncology developer. The company has a few options on the table, discussed in our report, but it remains to be seen in which direction the company will take its development program. Medivation took a hit this week after [...]
